Skip to main content

Table 2 Carcinoma-related treatment in 253 patients with breast carcinoma and diabetes (128 receiving and 125 not receiving metformin) and 320 patients with breast carcinoma without diabetes

From: Long-term use of metformin and the molecular subtype in invasive breast carcinoma patients – a retrospective study of clinical and tumor characteristics

Factor

Sub-group

Patients with breast carcinoma and diabetes without metformin (N = 125)

Patients with breast carcinoma and diabetes on metformin (N = 128)

Patients with breast carcinoma without diabetes (N = 320)

P1

P2

Breast surgical procedure

Quadrantectomy or lumpectomy

48

59

157

0.21

0.13

Mastectomy

77

69

163

  

Axillary surgical procedure

Sentinel node biopsy

54

61

147

0.43

0.73

Lymphadenectomy

71

67

173

Adjuvant chemotherapy

No

94

87

196

0.20

0.02

Yes

31

41

124

Adjuvant hormone therapy

No

14

15

76

0.89

0.0001

Yes

111

113

244

Adjuvant trastuzumab

No

118

115

285

0.17

0.22

Yes

7

13

35

Adjuvant radiotherapy

No

60

52

135

0.23

0.44

Yes

65

76

185

  1. P1: p-value (DM not on metformin vs. DM on metformin).
  2. P2: p-value (DM not on metformin vs. DM on metformin vs. controls).